Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?

被引:31
|
作者
Steib, A. [1 ]
Barre, J. [2 ]
Mertes, M. [3 ]
Morel, M. H. [4 ]
Nathan, N. [5 ]
Ozier, Y. [6 ]
Treger, M. [7 ]
Samama, C. M. [8 ]
机构
[1] Nouvel Hop Civil, Serv Anesthesie Reanimat Chirurg, Univ Hosp, Dept Anaesthesia & Intens Care, F-67091 Strasbourg, France
[2] Hop Robert Debre, Dept Anaesthesia & Intens Care, Reims, France
[3] Hop Cent, Dept Anaesthesia & Intens Care, Nancy, France
[4] Hop Jean Minjoz Besancon, Dept Anaesthesia & Intens Care, Univ Hosp, Besancon, France
[5] Ctr Hosp Univ Dupuytren, Dept Anaesthesia & Intens Care, Limoges, France
[6] Grp Hosp Cochin, Dept Anaesthesia & Intens Care, Paris, France
[7] Strasbourg Univ Hosp, Dept Biostat, Strasbourg, France
[8] Hop Hotel Dieu, Dept Anaesthesia & Intens Care, Paris, France
关键词
heparin bridging; INR; prothrombin complex concentrates; surgery; vitamin K; vitamin K antagonists; WARFARIN-ASSOCIATED COAGULOPATHY; INTERNATIONAL NORMALIZED RATIO; EXCESSIVE ANTICOAGULATION; OVER-ANTICOAGULATION; PHYTONADIONE; MANAGEMENT; REVERSAL; PLACEBO;
D O I
10.1111/j.1538-7836.2009.03685.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: After a vitamin K antagonist (VKA) overdose, 1-2 mg of oral vitamin K can lower the International Normalized Ratio (INR) to the therapeutic range. Objective: To establish whether oral vitamin K can substitute for heparin bridging and decrease the INR to < 1.5 before elective surgery. Methods: Patients on long-term VKAs were randomized either to heparin bridging after the last VKA dose on day - 5 before surgery (group H) or to VKA treatment until day - 2, followed by 1 mg of oral vitamin K on the day before surgery (group K). Blood clotting variables were assessed on days -5/-2, 1 and 0, and postoperatively. If the target INR was not achieved 2 h before incision, surgery was deferred or performed after injection of prothrombin complex concentrate (PCC). Results: In 30 of 94 included patients, baseline INR was outside the chosen range (18, INR < 2; 12, INR > 3.5), leaving 34 eligible patients in group H and 30 in group K. The groups were balanced in terms of body mass index, VKA treatment duration and indication, scheduled surgery, preoperative and postoperative hemoglobin, and blood loss. The INR was significantly higher in group K on days - 1 and 0 than in group H. An INR < 1.5 was not achieved in 20 group K patients (66%). Surgery was postponed or performed after PCC injection in 12 of these 20 patients. Conclusions: Oral vitamin K (1 mg) cannot substitute for heparin bridging before surgery. In addition, one-third of patients on VKAs were exposed to a risk of bleeding (overdose) or thrombosis (underdose), thus highlighting the need for new oral anticoagulants.
引用
收藏
页码:499 / 503
页数:5
相关论文
共 50 条
  • [21] Interaction of vitamin K antagonists with heparin affect monitoring by activated clotting times
    Muntwyler, Jorg
    Jost, Christine H. Attenhofer
    Diefenbacher, Werner
    Beer, Juerg H.
    Nikolic, Rada
    Amanpour, Feri
    Faeh-Gunz, Anja
    Naegeli, Barbara
    Straumann, Edwin H.
    Maurer, Dominik
    Candinas, Reto
    Dang, Lam
    Scharf, Christoph
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2010, 27 (02) : 89 - 94
  • [22] Reversal of vitamin K antagonists prior to urgent surgery
    Grobler, Chistine
    Callum, Jeannie
    McCluskey, Stuart A.
    CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 2010, 57 (05): : 458 - 467
  • [23] Vitamin K supplementation to decrease variability of International Normalized Ratio in patients on vitamin K antagonists: a literature review
    Ford, Sarah K.
    Moll, Stephan
    CURRENT OPINION IN HEMATOLOGY, 2008, 15 (05) : 504 - 508
  • [24] Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends
    Shiyovich, Arthur
    Shalev, Varda
    Chodick, Gabriel
    Tirosh, Matanya
    Katz, Amos
    Klar, Miriam M.
    Shuvy, Mony
    Pereg, David
    Minha, Sa'ar
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [25] MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists
    L'Allinec, Vincent
    Sibon, Igor
    Mazighi, Mikael
    Labreuche, Julien
    Kyheng, Maeva
    Boissier, Elodie
    Roy, Monica
    Gory, Benjamin
    Dargazanli, Cyril
    Desal, Hubert
    Lapergue, Bertrand
    Bourcier, Romain
    NEUROLOGY, 2020, 94 (08) : E842 - E850
  • [26] Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients
    Lafarge, Laurent
    Khayi, Fouzi
    Bel-Kamel, Anis
    Charhon, Nicolas
    Sarfati, Laura
    Falquet, Benoit
    Ducher, Michel
    Bourguignon, Laurent
    DRUGS & AGING, 2018, 35 (06) : 569 - 574
  • [27] Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease
    Voukalis, Christos
    Lip, Gregory Y. H.
    Shantsila, Eduard
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (15) : 2033 - 2047
  • [28] Epidemiology and management of bleeding in patients using vitamin K antagonists
    Levi, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 103 - 106
  • [29] Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older
    Manckoundia, Patrick
    Nuemi, Gilles
    Hacquin, Arthur
    Menu, Didier
    Rosay, Clementine
    Vovelle, Jeremie
    Nuss, Valentine
    Baudin-Senegas, Camille
    Barben, Jeremy
    Putot, Alain
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (09)
  • [30] Optimizing quality care for the oral vitamin K antagonists (VKAs)
    Pengo, Vittorio
    Denas, Gentian
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2018, : 332 - 338